News & Updates

First-line treatment with chemotherapy plus pembrolizumab followed by maintenance with pembrolizumab plus olaparib, with or without bevacizumab, appears to prolong progression-free survival (PFS) in advanced epithelial ovarian cancer without BRCA 1/2 mutations, according to data from the phase III ENGOT-ov43/GOG-3036/KEYLYNK-001 trial.

In the interim analysis of the phase III BRIGHT-2 study, adding the CDK4/6 inhibitor bireociclib to fulvestrant prolongs progression-free survival (PFS) in Chinese women with HR+/HER2- advanced breast cancer (ABC) who progressed on or after endocrine therapy (ET).

In women being treated for cervical cancer, chemotherapy and radiotherapy appear to have a substantial and lasting negative effect on sexual health, including satisfaction and desire, as shown in a descriptive cross-sectional study conducted in Brazil.

Adding metformin to letrozole and abemaciclib does not cause serious safety concerns and may even encourage favourable responses among patients with oestrogen receptor (ER)-positive recurrent endometrial cancer (EC), according to a phase II study presented at SGO 2025.

The use of progestin-only contraceptives may put women with a history of gestational diabetes mellitus (GDM) at risk of nonalcoholic fatty liver disease (NAFLD), as shown in a small prospective study.

Augmenting comprehensive clinical assessment (CCA) with invasive urodynamic investigations does not appear to benefit women with refractory overactive bladder (OAB) symptoms in the FUTURE* study presented at EAU25.